Mérieux Equity Partners, an investment platform specialized in the healthcare & nutrition sector, completed the acquisition of Laboratoires CTRS, a French pharmaceutical company. Financial terms were not disclosed. “Our entry into the capital of CTRS, as a reference shareholder alongside the founders and managers, is motivated by CTRS's demonstrated ability to identify, thanks to its unique network, unmet therapeutic needs and to respond to them by developing, then marketing, differentiated products. We intend to support CTRS internationally, especially in China, and help them expand their portfolio of niche products, while keeping the DNA of what has made CTRS successful since its creation,” Benoît Chastaing, Mérieux Equity Partners Managing Partner.